Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

• Christopher Maximilian Arends,
• Marlene Weiss,
• Friederike Christen,
• Claudia Eulenberg-Gustavus,
• Anthony Rousselle,
• Ralph Kettritz,
• Kai-Uwe Eckardt,
• Willy Chan,
• Kaja Hoyer,
• Mareike Frick,
• Lars Bullinger,
• Markus Bieringer,
• Adrian Schreiber,
• Frederik Damm

Affiliations

Christopher Maximilian Arends

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin

Marlene Weiss

Experimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin;Charité – Universitätsmedizin Berlin, Department of Nephrology and Intensive Care Medicine, Berlin

Friederike Christen

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin

Claudia Eulenberg-Gustavus

Experimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin

Anthony Rousselle

Experimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin

Ralph Kettritz

Experimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin;Charité – Universitätsmedizin Berlin, Department of Nephrology and Intensive Care Medicine, Berlin

Kai-Uwe Eckardt

Charité – Universitätsmedizin Berlin, Department of Nephrology and Intensive Care Medicine, Berlin

Willy Chan

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin

Kaja Hoyer

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin

Mareike Frick

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin

Lars Bullinger

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg

Markus Bieringer

HELIOS Klinikum Berlin-Buch, Department of Cardiology and Nephrology, Berlin, Germany

Adrian Schreiber

Experimental and Clinical Research Center, Charité, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin;Charité – Universitätsmedizin Berlin, Department of Nephrology and Intensive Care Medicine, Berlin

Frederik Damm

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg